The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Insight into Achieving & Maintaining Target Serum Urate Levels in Gout Patients

Insight into Achieving & Maintaining Target Serum Urate Levels in Gout Patients

November 11, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although studies have associated such factors as higher starting allopurinol doses (more than 100 mg/day) with maintaining target serum urate levels in gout patients, these studies were limited by the lack of a theoretical model, the consideration of an incomplete number of variables and inclusion of patients from a narrow geographic region.

You Might Also Like
  • Patients with Gout May Not Understand Serum Urate Goals & Treatments
  • Treating to Target in Gout: The Trouble with Serum Urate
  • Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels
Also By This Author
  • CD64 May Be an RA-Specific Biomarker

A new theoretical model has identified novel factors associated with maintaining serum urate levels of 6 mg/dL or less. These factors include co-morbidity, access to physicians and healthcare systems, allopurinol dosage and adherence, and disease severity. All of these factors were independently associated with achieving and maintaining a target serum urate level of 6 mg/dL or less. Jasvinder A. Singh, MBBS, MPH, staff rheumatologist at the Birmingham Veterans Association (VA) Medical Center, Alabama, and colleagues suggest providers may be able to target these, potentially, modifiable factors with interventions to successfully achieve and maintain target serum urate in gout patients. Researchers published a description of these factors online Aug. 15 in the Journal of Rheumatology.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“To our knowledge, no study to date has examined factors associated with maintaining target [serum urate levels],” write the authors in the discussion. “Our comprehensive, national cohort study performed robust analyses that controlled for patient, provider, systems, medication and disease severity factors, and advances the understanding of factors associated with target [serum urate]. Compared with non-rheumatology patients who saw rheumatologists (less than 3% patients) as the main providers for gout care were more likely to achieve target [serum urate], and maintain target [serum urate levels].”

The researchers used ICD-9 codes entered into VA databases to identify gout cases and co-morbidities. The database had a large sample size (198,839 unique patients with allopurinol use), which allowed investigators to include multiple potentially important covariates. The investigators identified 41,153 unique patients with 47,072 episodes who achieved a post-index serum urate level of less than 6 mg/dL, and 17,402 unique patients with 18,323 episodes who achieved a sustained post-index serum urate of less than 6 mg/dL. The analysis revealed that it took a mean of nine months to achieve the target serum urate level.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators applied the Andersen’s Behavioral Model of need to identify enabling and predisposing factors associated with the achievement of a serum urate of less than 6 mg/dL. When they analyzed the data using multivariable-adjusted models, they found several factors significantly associated with a higher rate of both successful outcomes. These factors were: normal body mass index, a Deyo-Charlson index score of 0, a rheumatologist as the main provider rather than a primary care practitioner, a healthcare facility located in the Midwest, the size of the VA hospital, healthcare access priority and lower (< 6 mg/dL) pre-index serum urate level.

Pages: 1 2 | Single Page

Filed Under: Conditions, Crystal Arthritis Tagged With: allopurinal, Allopurinol, Gout, serum urate levels

You Might Also Like:
  • Patients with Gout May Not Understand Serum Urate Goals & Treatments
  • Treating to Target in Gout: The Trouble with Serum Urate
  • Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels
  • Genes, Not Diet, Main Determinant of Urate Levels

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)